Trial Profile
A Phase II, Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of GSK1120212 Compared with Docetaxel in 2nd Line Subjects with Targeted Mutations (KRAS, NRAS, BRAF, MEK1) in Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC Stage IV)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Oct 2023
Price :
$35
*
At a glance
- Drugs Trametinib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 21 Oct 2013 Results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
- 04 Jun 2013 Primary endpoint 'Progression-free-survival-rate' has not been met.
- 04 Jun 2013 Status changed from active, no longer recruiting to discontinued.